Cancer risk assessment at the atomic level

Cancer Research

Volumn 66, Issue 4, 2006, Pages 1897-1899

  Monteiro, Alvaro N A ^a   Couch, Fergus J ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOM; CANCER RISK; GENE MUTATION; HUMAN; MISSENSE MUTATION; ONCOGENE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN FUNCTION; RELIABILITY; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE; VALIDATION PROCESS;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION, MISSENSE; NEOPLASMS; RISK ASSESSMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33644515288     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3034     Document Type: Review

References (32)

1. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 2005;23:1656-63.
2. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-90.
3. Kahn P. Genome: coming to grips with genes and risk. Science 1996;274:496-8.
4. Fleming MA, Potter JD, Ramirez CJ, Ostrander GK, Ostrander EA. Understanding missense mutations in the BRCA1 gene: an evolutionary approach. Proc Natl Acad Sci U S A 2003;100:1151-6.
5. Abkevich V, Zharkikh A, Deffenbaugh AM, et al. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 2004;41:492-507.
6. Kashuk CS, Stone EA, Grice EA, et al. Phenotype-genotype correlation in Hirschsprung disease is illuminated by comparative analysis of the RET protein sequence. Proc Natl Acad Sci U S A 2005;102:8949-54.
7. Harrison SC. Variation on an Src-like theme. Cell 2003;112:737-40.
8. Mackinnon R. Nobel Lecture. Potassium channels and the atomic basis of selective ion conduction. Biosci Rep 2004;24:75-100.
9. Williams RS, Green R, Glover JN. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol 2001;8:838-42.
10. Williams RS, Glover JN. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation. J Biol Chem 2003;278:2630-5.
11. Ekblad CM, Wilkinson HR, Schymkowitz JW, Rousseau F, Freund SM, Itzhaki LS. Characterisation of the BRCT domains of the breast cancer susceptibility gene product BRCA1. J Mol Biol 2002;320:431-42.
12. Williams RS, Lee MS, Hau DD, Glover JN. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat Struct Mol Biol 2004;11:519-25.
13. Glover JN, Williams RS, Lee MS. Interactions between BRCT repeats and phosphoproteins: tangled up in two. Trends Biochem Sci 2004;29:579-85.
14. Baer R. With the ends in sight: images from the BRCA1 tumor suppressor. Nat Struct Biol 2001;8:822-4.
15. Gaiser OJ, Ball LJ, Schmieder P, et al. Solution structure, backbone dynamics, and association behavior of the C-terminal BRCT domain from the breast cancer-associated protein BRCA1. Biochemistry 2004;43:15983-95.
16. Shiozaki EN, Gu L, Yan N, Shi Y. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling. Mol Cell 2004;14:405-12.
17. Botuyan MV, Nomine Y, Yu X, et al. Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains. Structure (Camb) 2004;12:1137-46.
18. Joo WS, Jeffrey PD, Cantor SB, Finnin MS, Livingston DM, Pavletich NP. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. Genes Dev 2002;16:583-93.
19. Clapperton JA, Manke IA, Lowery DM, et al. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol 2004;11:512-8.
20. Yang H, Jeffrey PD, Miller J, et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 2002;297:1837-48.
21. Brzovic PS, Rajagopal P, Hoyt DW, King MC, Klevit RE. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat Struct Biol 2001;8:833-7.
22. Chance MR, Fiser A, Sali A, et al. High-throughput computational and experimental techniques in structural genomics. Genome Res 2004;14:2145-54.
23. Mark WY, Liao JC, Lu Y, et al. Characterization of segments from the central region of BRCA1: an intrinsically disordered scaffold for multiple protein-protein and protein-DNA interactions? J Mol Biol 2005;345:275-87.
24. Sturdy A, Naseem R, Webb M. Purification and characterisation of a soluble N-terminal fragment of the breast cancer susceptibility protein BRCA1. J Mol Biol 2004;340:469-75.
25. Tavtigian SV, Deffenbaugh AM, Yin L, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet. In press 2006.
26. Karchin R, Diekhans M, Kelly L, et al. LS-SNP: largescale annotation of coding non-synonymous SNPs based on multiple information sources. Bioinformatics 2005;21:2814-20.
27. Sunyaev S, Ramensky V, Koch I, Lathe W III, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet 2001;10:591-7.
28. Stitziel NO, Tseng YY, Pervouchine D, Goddeau D, Kasif S, Liang J. Structural location of disease-associated single-nucleotide polymorphisms. J Mol Biol 2003;327:1021-30.
29. Mirkovic N, Marti-Renom MA, Weber BL, Sali A, Monteiro AN. Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res 2004;64:3790-7.
30. Marx J. Zeroing in on individual cancer risk. Science 1991;253:612-6.
31. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
32. Weir B, Zhao X, Meyerson M. Somatic alterations in the human cancer genome. Cancer Cell 2004;6:433-8.